Denali plans to proceed medical improvement of DNL593, which is designed to ship progranulin to the mind utilizing TransportVehicle™ technologyResults from ongoing Section 1/2 examine in sufferers with FTD-GRN anticipated by the top of 2026
SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) immediately introduced that it has acquired notification from Takeda of its determination to terminate the collaboration settlement between the 2 firms to co-develop and co-commercialize DNL593 (PTV:PGRN). The choice was pushed by strategic issues and isn’t associated to efficacy or security knowledge. DNL593 is an investigational progranulin substitute remedy using Denali’s Protein TransportVehicle™ (PTV) to ship progranulin throughout the blood-brain barrier to the mind for the therapy of frontotemporal dementia-granulin (FTD-GRN). Denali has led improvement actions and can regain full management of DNL593 and its mental property portfolio.
“While we have greatly valued our partnership, we are pleased to regain full ownership of DNL593. We remain confident in the scientific rationale and the data generated to date, and we look forward to advancing DNL593 independently. We plan to report results from the ongoing Phase 1/2 trial by the end of 2026,” mentioned Ryan Watts, Ph.D., Chief Government Officer of Denali Therapeutics. “Our TransportVehicle platform is the first FDA-approved blood-brain barrier-crossing technology, enabling a robust portfolio with broad potential across neurodegenerative diseases like frontotemporal dementia, where there are no currently approved treatment options to slow the progression of this devasting disease.”
As beforehand disclosed, knowledge from the continuing Section 1/2 examine of DNL593, together with biomarker outcomes, are anticipated by the top of 2026. Enrollment on this examine is accomplished with a complete of 40 contributors with FTD-GRN. Interim outcomes from Half A of the Section 1/2 examine in wholesome volunteers demonstrated dose-dependent will increase in cerebrospinal fluid progranulin ranges, according to strong mind supply of DNL593. DNL593 was typically nicely tolerated, and there have been no vital security alerts to this point.
About Frontotemporal Dementia (FTD)
More Read
FTD is the most typical type of dementia in folks below 60 years of age. Whereas the development of signs varies by particular person, FTD brings an inevitable decline in perform along with modifications in character and social behaviors, and typically language and/or motor dysfunction. Mutations within the granulin (GRN) gene, which encodes the progranulin (PGRN) protein, typically lead to lowered ranges of PGRN and are amongst the most typical genetic causes of FTD. There are at present no authorised medicines to cease or sluggish the development of FTD or FTD-GRN.
In regards to the Denali TransportVehicle™ Platform
The blood-brain barrier (BBB) is crucial in sustaining the mind’s microenvironment and defending it from dangerous substances and pathogens circulating within the bloodstream. Traditionally, the BBB has posed vital challenges to drug improvement for central nervous system ailments by stopping most medicine from reaching the mind in therapeutically related concentrations. Denali’s TransportVehicle™ (TV) platform is a proprietary expertise designed to successfully ship massive therapeutic molecules resembling antibodies, enzymes and oligonucleotides all through the entire physique, together with the mind, by crossing the BBB after intravenous administration. The TV platform relies on engineered Fc domains that bind to particular pure transport receptors, resembling transferrin receptor and CD98 heavy chain amino acid transporter, that are expressed on the BBB and ship the TV and its therapeutic cargo to the mind by means of receptor-mediated transcytosis. In animal fashions, antibodies and enzymes engineered with the TV platform reveal greater than 10- to 30-fold larger mind publicity than comparable antibodies and enzymes with out this expertise. Oligonucleotides engineered with the TV platform reveal greater than a 1,000-fold larger mind publicity in primates than systemically delivered oligonucleotides with out this expertise. Improved publicity and broad distribution within the mind might improve therapeutic efficacy by enabling widespread achievement of therapeutically related concentrations of product candidates. The TV platform has been clinically validated and 5 TV-enabled packages are at present in medical improvement.
More Read
About Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology firm pioneering a brand new class of biotherapeutics designed to cross the blood-brain barrier utilizing its proprietary TransportVehicle™ platform. With a clinically validated supply platform and a rising portfolio of therapeutic candidates throughout all phases of improvement, Denali is advancing towards its purpose of delivering efficient medicines to rework life for folks with neurodegenerative ailments, lysosomal storage issues and different critical ailments. For extra data, please go to www.denalitherapeutics.com.
Ahead-Wanting Statements
This press launch comprises forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995. Ahead-looking statements expressed or implied on this press launch embrace, however usually are not restricted to, plans, timelines and expectations associated to Denali’s TransportVehicle™ platform, together with its potential software throughout present and future product candidates and its capacity to ship therapeutics to the mind; plans, timelines and expectations associated to DNL593, together with the timing and availability of information readouts from the continuing Section 1/2 examine, the importance of interim knowledge from the Section 1/2 examine together with with respect to tolerability and security, and the potential therapeutic advantage of DNL593; and statements by Denali’s Chief Government Officer. Precise outcomes might differ materially from these expressed or implied by these forward-looking statements as a result of a wide range of dangers and uncertainties. These embrace, however usually are not restricted to, uncertainties associated to the FDA’s insurance policies and accelerated approval program; dangers arising from opposed financial circumstances and their affect on Denali’s enterprise and operations; the potential of occasions or modifications that might result in the termination of Denali’s collaboration agreements; challenges related to Denali’s transition to a business firm; the flexibility of Denali and its collaborators to finish the event and, if authorised, the commercialization of product candidates; difficulties in affected person enrollment for ongoing and future medical trials; whether or not the present ongoing trials have been powered sufficiently to reveal approvability to regulatory businesses; reliance on third-party producers and suppliers for medical trial supplies; dependence on the profitable improvement of Denali’s blood-brain barrier platform expertise and associated packages; potential delays or failures in assembly anticipated medical trial timelines; the chance that promising preclinical profiles will not be replicated in medical settings; discrepancies between preclinical, early-stage or preliminary medical outcomes and outcomes from later-stage trials; the prevalence of great opposed occasions or different undesirable unintended effects; the uncertainty surrounding regulatory approvals required for commercialization within the U.S., Europe or different worldwide jurisdictions; Denali’s capacity to advance a pipeline of product candidates or develop commercially profitable merchandise; developments regarding Denali’s rivals and its trade, together with competing product candidates and therapies; Denali’s capacity to acquire, keep or shield mental property rights associated to its product candidates; the implementation and success of Denali’s strategic plans for its enterprise, product candidates and blood-brain barrier platform expertise; Denali’s capacity to acquire extra capital to finance its operations, as wanted; Denali’s capacity to precisely forecast future monetary ends in the present atmosphere; and different dangers and uncertainties, together with these described in Denali’s most up-to-date Annual and Quarterly Experiences on Type 10-Okay filed with the Securities and Trade Fee (SEC) on February 26, 2026, and Denali’s future stories to be filed with the SEC. Aside from AVLAYAH™ (tividenofusp alfa-eknm), Denali’s product candidates are investigational, and their security and efficacy profiles haven’t but been established. Denali doesn’t undertake any obligation to replace or revise any forward-looking statements, to evolve these statements to precise outcomes or to make modifications in Denali’s expectations, besides as required by regulation.
